Drug therapy for myelodysplastic syndrome: building evidence for action
- PMID: 16532501
- DOI: 10.1002/cncr.21793
Drug therapy for myelodysplastic syndrome: building evidence for action
Comment on
-
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.Cancer. 2006 Apr 15;106(8):1794-803. doi: 10.1002/cncr.21792. Cancer. 2006. PMID: 16532500 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
